AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Trading 08-06 11:26:07

95.050

-0.450

-0.47%

High98.200	Low94.350	Vol3.17M
Open96.700	D1 Closing95.500	Amplitude4.03%
Mkt Cap87.54B	Tradable Cap87.54B	Total Shares921.00M
T/O304.11M	T/O Rate0.34%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":95.05,"timestamp":1785986766604,"preClose":95.5,"halted":0,"volume":3172975,"delay":0,"changeRate":-0.004712041884816783,"floatShares":921000000,"shares":921000000,"eps":-1.4329100380087376,"marketStatus":"Trading","change":-0.45,"latestTime":"08-06 11:26:07","open":96.7,"high":98.2,"low":94.35,"amount":304113847,"amplitude":0.040314,"askPrice":95.1,"askSize":23000,"bidPrice":94.9,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-1.4329100380087376,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1785988800000},"marketStatusCode":2,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":95.5,"openAndCloseTimeList":[[1785979800000,1785988800000],[1785992400000,1786003200000]],"volumeRatio":1.378356,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.7127,"impliedVolPercentile":0.8507},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"1149383350","title":"Movement Alert｜AKESO Rises 3.04% in Regular Trading, Innovative Drug Sector Collectively Strengthens Ahead of Major Academic Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=1149383350","media":"Market Focus","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149383350?lang=en_us&edition=fundamental","pubTime":"2026-08-05 14:59","pubTimestamp":1785913177,"startTime":"0","endTime":"0","summary":"On August 5, AKESO rose 3.04% in regular trading, trading at 96.6 HKD/share, with turnover of HKD 392 million. The gain was primarily driven by broad-based strength across the innovative drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656937496","title":"Akeso (SEHK:9926) Dosed Its First AK138D1 Patient, Is The 47% Undervalued View Too Bullish?","url":"https://stock-news.laohu8.com/highlight/detail?id=2656937496","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656937496?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:20","pubTimestamp":1785756010,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) is back in focus after dosing the first patient in a Phase Ib/II trial of its HER3 antibody drug conjugate AK138D1 for advanced non small cell lung cancer.\nSee our latest analysis for Akeso.\nAkeso’s latest trial milestone comes after a period where sentiment has cooled, with the share price at HK$91.95 and the 1-year total shareholder return down 39.55%, although the 3-year total shareholder return remains very strong.\nIf Akeso’s oncology work has caught your attention, this...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-dosed-its-first-ak138d1-patient-is-the-47-und","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-dosed-its-first-ak138d1-patient-is-the-47-und","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348767384.USD","LU0348783233.USD","LU0634319403.HKD","09926","LU1961090484.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU0348735423.USD","KURE","IE00B543WZ88.USD","LU0417516902.SGD","LU0348766576.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","BK1574","LU0348827113.USD","LU2778985437.USD","LU0540923850.HKD","LU2399975544.HKD","LU1720050803.USD","LU1794554557.SGD","LU2476274720.SGD","LU0417516738.SGD","LU2476274308.USD","BK1161","LU0561508036.HKD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135680900","title":"China's domestic innovative drugs set for overseas revenue breakthrough as policy support strengthens","url":"https://stock-news.laohu8.com/highlight/detail?id=1135680900","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135680900?lang=en_us&edition=fundamental","pubTime":"2026-07-31 07:16","pubTimestamp":1785453390,"startTime":"0","endTime":"0","summary":"The Shanghai municipal government released its \"15th Five-Year Plan for Health Development\" on July 30, which includes measures to boost the research and development of innovative drugs and medical...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU1770034418.SGD","LU2476274308.USD","BK1161","LU2097828631.EUR","LU2399975544.HKD","LU0561508036.HKD","LU2097828805.USD","09688","MEDX","06978","09926","IBBQ","LU0348784397.USD","HK0000165453.HKD","LU2097828474.EUR","LU1719994722.HKD","BK4588","LU0307460666.USD","LU0417516738.SGD","LU2097828557.USD","LU2778985437.USD","BK4585","KURE","LU0348825331.USD","LU1720050803.USD","LU0348783233.USD","LU2328871848.SGD","BK1574","LU0502904849.HKD","IE00BPRC5H50.USD","LU2476274720.SGD","VXUS","LU0417516571.SGD","LU1303224171.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1969619763.USD","LU1251922891.USD","LU0348767384.USD","BK1588","LU1961090484.USD","LU0634319403.HKD","159992","BK1589","LU0455707207.USD","LU0348827113.USD","LU0588546209.SGD","LU2242644610.SGD","LU0348766576.USD","LU0348735423.USD","06160","LU0417516902.SGD","KCAI","LU2488822045.USD","LNGR","LU0540923850.HKD","BK1500","01801","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192482124","title":"Movement Alert｜AKESO Falls 3.29% in Regular Trading, Share Option Exercise Price Inversion Compounds Biotech Sector Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=1192482124","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192482124?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:24","pubTimestamp":1785381871,"startTime":"0","endTime":"0","summary":"On July 30, AKESO fell 3.29% in regular trading, trading at 92.4 HKD/share, with turnover of 3.27 billion HKD. The decline reflects continued pressure from a share option exercise price inversion and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AKESO Falls; Share Option Exercise Price Inversion Compounds Biotech Sector Weakness","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655853679","title":"China's Biotechnology Success Meets Increasing US Scrutiny, Analytics Firm Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655853679","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655853679?lang=en_us&edition=fundamental","pubTime":"2026-07-29 12:19","pubTimestamp":1785298770,"startTime":"0","endTime":"0","summary":"China's rise as a global biotechnology innovation hub has worried the U.S., driving Washington to scrutinize the country's competitiveness and technological leadership rather than scientific advances alone, analytics firm GlobalData said in a Tuesday press release.The implications of China's emergence extends \"beyond healthcare innovation to include pharmaceutical supply-chain resilience, economic competitiveness, and national security,\" GlobalData healthcare analyst Edita Hamzic said.GlobalData cited Akeso's  presentation of its ivonescimab therapy at the American Society of Clinical Oncology as the first drug developed from a China-only clinical trial for non-small cell lung cancer patients as a display of China's scientific progress.It also cited Wuxi AppTec's  inclusion in the U.S. Department of Defense's Section 1260H list of \"Chinese military companies\" that could affect its eligilibity for future U.S. governemnt contracts.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348767384.USD","LU1979443071.USD","LU0320764599.SGD","LU0348735423.USD","LU2488822045.USD","LU1969619763.USD","LU2125910500.SGD","IE00B543WZ88.USD","LU0417516902.SGD","LU0348784397.USD","603259","LU2778985437.USD","LU2399975544.HKD","LU0348827113.USD","LU0708995583.HKD","LU2476274308.USD","IE00BPRC5H50.USD","LU2328871848.SGD","LU0540923850.HKD","LU1794554557.SGD","LU2495084118.USD","LU1770034418.SGD","LU1808992512.USD","LU1961090484.USD","LU1720050803.USD","LU0611395673.USD","LU0348766576.USD","LU2045819591.USD","LU1997244956.HKD","BK1576","LU0348825331.USD","KURE","LU0348783233.USD","LU2476274720.SGD","LU0561508036.HKD","BK1141","LU0052750758.USD","LU0417516738.SGD","BK1583","BK0216","02359","IE00B5MMRT66.SGD","LU1997245094.SGD","LU2242644610.SGD","LU1046422090.SGD","LU0417516571.SGD","BK1161","LU1251922891.USD","09926","LU0456842615.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194999188","title":"Movement Alert｜AKESO Falls 3.04% in Regular Trading, Share Option Grant Sparks Dilution Concerns Amid Biotech Sector Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=1194999188","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194999188?lang=en_us&edition=fundamental","pubTime":"2026-07-28 10:47","pubTimestamp":1785206827,"startTime":"0","endTime":"0","summary":"On July 28, AKESO declined 3.04% in regular trading, trading at HK$95.75/share, with turnover of HK$183 million.On the news front, the company announced on July 26 that it granted 3,603,500 share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AKESO Falls as Share Option Grant Sparks Dilution Concerns Amid Biotech Sector Pullback","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654027898","title":"Akeso Doses First Patient in Phase Ib/II NSCLC Trial of HER3 ADC Ak138d1 with Ivonescimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2654027898","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654027898?lang=en_us&edition=fundamental","pubTime":"2026-07-28 10:36","pubTimestamp":1785206161,"startTime":"0","endTime":"0","summary":"Akeso doses first patient in Phase Ib/II NSCLC trial of HER3 ADC AK138D1 with ivonescimabAkeso dosed the first patient in a Phase Ib/II study of its HER3 ADC AK138D1, alone or with ivonescimab, in adv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL5VnSD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2399975544.HKD","LU0634319403.HKD","LU0348766576.USD","LU0417516738.SGD","09926","LU0348784397.USD","BK1161","LU0348827113.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","KURE","LU0348735423.USD","LU1720050803.USD","LU1794554557.SGD","LU1961090484.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU2476274308.USD","LU0540923850.HKD","LU2778985437.USD","LU2488822045.USD","LU0348825331.USD","LU2476274720.SGD","LU0561508036.HKD","BK1574","LU0348783233.USD","LU0417516902.SGD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654309720","title":"Nomura Adjusts Akeso's Price Target to HK$138.29 From HK$142.50, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2654309720","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654309720?lang=en_us&edition=fundamental","pubTime":"2026-07-27 15:18","pubTimestamp":1785136736,"startTime":"0","endTime":"0","summary":"Akeso (HKG:9926) has an average rating of buy and mean price target of HK$170.79, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348735423.USD","LU1961090484.USD","LU2476274308.USD","LU1794554557.SGD","BK1161","LU0417516902.SGD","LU0348825331.USD","LU2476274720.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0634319403.HKD","LU0561508036.HKD","KURE","IE00B543WZ88.USD","LU0417516571.SGD","IE00BPRC5H50.USD","LU0348767384.USD","LU2399975544.HKD","09926","LU0417516738.SGD","LU1720050803.USD","LU2488822045.USD","BK1574","LU0348784397.USD","LU0540923850.HKD","LU0348783233.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193396300","title":"AKESO (09926) Grants 3,603,500 Share Options and 1,648,500 Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1193396300","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193396300?lang=en_us&edition=fundamental","pubTime":"2026-07-26 19:58","pubTimestamp":1785067091,"startTime":"0","endTime":"0","summary":"AKESO (09926) has announced that on July 24, 2026, the company granted 3,603,500 share options to 167 grantees under its share option scheme, with an exercise price of HKD 99.5 per option.On the same...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516738.SGD","KURE","LU0634319403.HKD","BK1161","LU2399975544.HKD","LU1720050803.USD","LU0348735423.USD","09926","IE00B543WZ88.USD","LU0348827113.USD","LU0417516571.SGD","LU0348784397.USD","LU2778985437.USD","LU0348767384.USD","LU0348766576.USD","LU2476274308.USD","IE00BPRC5H50.USD","LU2476274720.SGD","LU1794554557.SGD","LU2488822045.USD","LU0348825331.USD","LU0561508036.HKD","BK1574","LU0417516902.SGD","LU0348783233.USD","LU1961090484.USD","IE00B5MMRT66.SGD","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654066635","title":"Akeso Grants 3,603,500 Share Options at HK$ 99.5 Exercise Price Under Employee Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2654066635","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654066635?lang=en_us&edition=fundamental","pubTime":"2026-07-26 19:52","pubTimestamp":1785066759,"startTime":"0","endTime":"0","summary":"Akeso grants 3,603,500 share options at HK$ 99.5 exercise price under employee incentive planAkeso granted 3,603,500 share options on July 24, 2026 to 167 directors, executives, and employees.Options ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260726:nNDL2tnMB7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU1961090484.USD","LU2476274308.USD","LU1794554557.SGD","BK1161","LU0417516902.SGD","LU0348825331.USD","LU2476274720.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0634319403.HKD","LU0561508036.HKD","KURE","IE00B543WZ88.USD","LU0417516571.SGD","IE00BPRC5H50.USD","LU0348767384.USD","LU2399975544.HKD","09926","LU0417516738.SGD","LU1720050803.USD","LU2488822045.USD","BK1574","LU0348784397.USD","LU0540923850.HKD","LU0348783233.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653003567","title":"Akeso (SEHK:9926) Partners With MSK, Is The Discount To Fair Value Justified?","url":"https://stock-news.laohu8.com/highlight/detail?id=2653003567","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653003567?lang=en_us&edition=fundamental","pubTime":"2026-07-24 22:24","pubTimestamp":1784903090,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) has drawn fresh investor attention after partnering with Memorial Sloan Kettering Cancer Center on a Phase II study of cadonilimab based therapy for HER2 negative gastric and gastroesophageal junction adenocarcinoma.\nSee our latest analysis for Akeso.\nAkeso's latest collaboration arrives after a mixed stretch in the stock, with the 7 day share price return up 12.62% and the 1 month share price return up 13.71%, but the year to date share price return down 12.18% and the 1...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-partners-with-msk-is-the-discount-to-fair-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-partners-with-msk-is-the-discount-to-fair-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348767384.USD","LU0348783233.USD","LU0634319403.HKD","09926","LU1961090484.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU0348735423.USD","KURE","IE00B543WZ88.USD","LU0417516902.SGD","LU0348766576.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","BK1574","LU0348827113.USD","LU2778985437.USD","LU0540923850.HKD","LU2399975544.HKD","LU1720050803.USD","LU1794554557.SGD","LU2476274720.SGD","LU0417516738.SGD","LU2476274308.USD","BK1161","LU0561508036.HKD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160418569","title":"Movement Alert｜AKESO Falls 3.11% in Regular Trading, Profit-Taking After Two-Day Rally Amid Sector Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=1160418569","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160418569?lang=en_us&edition=fundamental","pubTime":"2026-07-24 13:22","pubTimestamp":1784870555,"startTime":"0","endTime":"0","summary":"On July 24, AKESO fell 3.11% in regular trading, trading at 99.55 HKD/share, with turnover of 452 million HKD.The decline comes after two consecutive sessions of strong gains, with the stock having...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161526938","title":"Movement Alert｜AKESO Rises 4.15% in Regular Trading, Ivonescimab Global Phase III OS Data Continues to Improve with New Renal Cancer Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=1161526938","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161526938?lang=en_us&edition=fundamental","pubTime":"2026-07-23 11:04","pubTimestamp":1784775882,"startTime":"0","endTime":"0","summary":"On July 23, AKESO rose 4.15% in regular trading, trading at 104.3 HKD/share, with turnover of HKD 371 million. The stock was driven by multiple positive catalysts from its overseas partner Summit...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653025767","title":"How Akeso’s IO 2.0 Bispecific Push At Akeso (SEHK:9926) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2653025767","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653025767?lang=en_us&edition=fundamental","pubTime":"2026-07-23 01:19","pubTimestamp":1784740789,"startTime":"0","endTime":"0","summary":"Akeso recently announced a collaboration with Memorial Sloan Kettering Cancer Center to run a Phase II trial of its PD-1/CTLA-4 bispecific antibody cadonilimab in a perioperative combination regimen for locally advanced, resectable HER2-negative gastric or gastroesophageal junction adenocarcinoma in the United States.\nThis partnership, alongside Akeso’s broader IO 2.0 and ADC 2.0 pipeline including Phase II work in advanced non-small cell lung cancer, underscores how bispecific backbones are...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/how-akesos-io-20-bispecific-push-at-akeso-sehk9926-has-chang","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/how-akesos-io-20-bispecific-push-at-akeso-sehk9926-has-chang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2399975544.HKD","LU0634319403.HKD","LU0348766576.USD","LU0417516738.SGD","09926","LU0348784397.USD","BK1161","LU0348827113.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","KURE","LU0348735423.USD","LU1720050803.USD","LU1794554557.SGD","LU1961090484.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU2476274308.USD","LU0540923850.HKD","LU2778985437.USD","LU2488822045.USD","LU0348825331.USD","LU2476274720.SGD","LU0561508036.HKD","BK1574","LU0348783233.USD","LU0417516902.SGD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128741716","title":"Movement Alert｜Akeso Rises 4.39% in Regular Trading, Novel Bispecific ADC Completes First Patient Dosing in Phase II NSCLC Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1128741716","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128741716?lang=en_us&edition=fundamental","pubTime":"2026-07-22 09:43","pubTimestamp":1784684601,"startTime":"0","endTime":"0","summary":"On July 22, Akeso rose 4.39% in regular trading, trading at HK$100.8/share, with turnover of HK$258 million.On the news front, Akeso recently announced that its novel Trop2/Nectin-4 bispecific...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158719553","title":"Movement Alert｜Akeso Bio Falls 3.05% in Regular Trading, Trading at HK$90.5","url":"https://stock-news.laohu8.com/highlight/detail?id=1158719553","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158719553?lang=en_us&edition=fundamental","pubTime":"2026-07-21 10:14","pubTimestamp":1784600099,"startTime":"0","endTime":"0","summary":"On July 21, Akeso Bio fell 3.05% in regular trading, trading at HK$90.5/share, with turnover of HK$193 million.Within the Biotechnology sector where Akeso Bio belongs, the overall sector performance...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652902262","title":"Akeso Says Press Release Available on Phase II Dosing of Ak146d1 with Ivonescimab in Advanced NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2652902262","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652902262?lang=en_us&edition=fundamental","pubTime":"2026-07-20 13:32","pubTimestamp":1784525570,"startTime":"0","endTime":"0","summary":"Akeso says press release available on Phase II dosing of AK146D1 with ivonescimab in advanced NSCLCAkeso published a press release on July 20, 2026, reporting first patient dosed in a Phase II NSCLC s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL34wdlZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274720.SGD","LU0348784397.USD","LU2476274308.USD","LU0348827113.USD","LU2488822045.USD","09926","LU0561508036.HKD","LU1794554557.SGD","LU1720050803.USD","LU0417516571.SGD","BK1574","IE00BPRC5H50.USD","LU0348767384.USD","LU0634319403.HKD","LU1961090484.USD","LU0348783233.USD","LU2778985437.USD","LU0348735423.USD","LU2399975544.HKD","KURE","IE00B543WZ88.USD","BK1161","LU0417516902.SGD","LU0540923850.HKD","LU0417516738.SGD","LU0348766576.USD","IE00B5MMRT66.SGD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652977262","title":"Akeso Doses First Patient in Phase Ii Study of Novel Trop2/nectin-4 Bispecific ADC (ak146d1) in Combination with Ivonescimab for Advanced Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2652977262","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652977262?lang=en_us&edition=fundamental","pubTime":"2026-07-20 13:32","pubTimestamp":1784525555,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUA9R76KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0634319403.HKD","IE00B543WZ88.USD","LU0348766576.USD","LU0561508036.HKD","BK1161","LU2778985437.USD","LU2488822045.USD","LU2399975544.HKD","LU2476274308.USD","LU1794554557.SGD","09926","LU0348784397.USD","LU0540923850.HKD","LU0348767384.USD","IE00B5MMRT66.SGD","LU1720050803.USD","LU2476274720.SGD","LU0348783233.USD","LU0348735423.USD","BK1574","LU0417516571.SGD","LU0417516738.SGD","LU0417516902.SGD","LU0348827113.USD","IE00BPRC5H50.USD","LU0348825331.USD","KURE","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185053835","title":"HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185053835","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185053835?lang=en_us&edition=fundamental","pubTime":"2026-07-20 11:36","pubTimestamp":1784518575,"startTime":"0","endTime":"0","summary":"Monday, July 20, Hong Kong biomedical shares staged a broad rally. $REMEGEN(09995)$, $WUXI XDC(02268)$ and $KEYMED BIO-B(02162)$ climbed more than 8%, while $JUNSHI BIO(01877)$ gained over 7% and $AKESO(09926)$ advanced above 6%. $WUXI BIO(02269)$ edged up nearly 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","09995","01877","09926","02162","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197510337","title":"Movement Alert｜Akeso Rises 3.17% in Regular Trading, Biotech Sector Rallies Broadly with Multiple Buy Ratings Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=1197510337","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197510337?lang=en_us&edition=fundamental","pubTime":"2026-07-20 09:52","pubTimestamp":1784512347,"startTime":"0","endTime":"0","summary":"On July 20, Akeso rose 3.17% in regular trading, trading at HK$91.55/share, with turnover of HK$159 million. The gain was driven by a broad rally across the biotechnology sector.On the news front,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0016},{"period":"1month","weight":-0.0628},{"period":"3month","weight":-0.3075},{"period":"6month","weight":-0.0535},{"period":"1year","weight":-0.4141},{"period":"ytd","weight":-0.1549}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0974},{"period":"3month","weight":-0.0267},{"period":"6month","weight":-0.0243},{"period":"1year","weight":0.0407},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.077852},{"month":7,"riseRate":0.571429,"avgChangeRate":0.084887},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.00429},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}